Cspc Innovation Pharmaceutical Co.,Ltd.(300765),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

300765 Cspc Innovation Pharmaceutical Co.,Ltd.

Closed 07-28 15:00:00

38.90

+2.48

+6.81%

High39.40	Low37.48	Vol34.13M
Open37.88	D1 Closing36.42	Amplitude5.27%
Mkt Cap54.65B	Tradable Cap54.65B	Total Shares1.41B
T/O1.31B	T/O Rate2.43%	Tradable Shares1.41B
P/B19.85	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"300765","market":"SZ","secType":"STK","nameCN":"Cspc Innovation Pharmaceutical Co.,Ltd.","latestPrice":38.9,"timestamp":1785222186000,"preClose":36.42,"halted":0,"volume":34128074,"delay":0,"changeRate":0.0681,"floatShares":1405000000,"shares":1405000000,"eps":-0.2194,"marketStatus":"Closed","change":2.48,"latestTime":"07-28 15:00:00","open":37.88,"high":39.4,"low":37.48,"amount":1312000000,"amplitude":0.0527,"askPrice":38.9,"askSize":374,"bidPrice":38.89,"bidSize":105,"shortable":0,"etf":0,"ttmEps":-0.2194,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1785288600000},"marketStatusCode":5,"adr":0,"adjPreClose":36.42,"symbolType":"stock","openAndCloseTimeList":[[1785202200000,1785209400000],[1785214800000,1785222000000]],"highLimit":40.06,"lowLimit":32.78,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1404592944,"isCdr":false,"pbRate":19.85,"roa":"--","roe":"--","epsLYR":-0.1731,"committee":-0.005413,"marketValue":54639000000,"turnoverRate":0.0243,"status":0,"floatMarketCap":54639000000},"requestUrl":"/m/hq/s/300765/wiki","defaultTab":"wiki","newsList":[{"id":"1107941055","title":"Cspc Innovation Pharmaceutical forecasts net profit of 1.18 to 1.36 billion yuan for first half of 2026, reversing year-on-year loss","url":"https://stock-news.laohu8.com/highlight/detail?id=1107941055","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107941055?lang=en_us&edition=fundamental","pubTime":"2026-07-27 17:38","pubTimestamp":1785145095,"startTime":"0","endTime":"0","summary":"Cspc Innovation Pharmaceutical Co., Ltd. (300765.SZ) has released its performance forecast for the first half of 2026, projecting a net profit attributable to shareholders of the listed company...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654016865","title":"CSPC Innovation Pharma, CSPC Pharmaceutical Group Unit, Forecasts H1 Net Profit at 1.18 Billion-1.36 Billion Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=2654016865","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654016865?lang=en_us&edition=fundamental","pubTime":"2026-07-27 17:34","pubTimestamp":1785144884,"startTime":"0","endTime":"0","summary":"CSPC Innovation Pharma, CSPC Pharmaceutical Group unit, forecasts H1 net profit at 1.18 billion-1.36 billion yuanCSPC Innovation Pharmaceutical, a subsidiary of CSPC Pharmaceutical Group, guided for H","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nNDL9WrKMv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","LU1923622614.USD","03165","AZN.UK","IE0008368742.USD","IE0008369823.USD","LU0545039389.USD","LU1078025761.USD","LU1328277881.USD","LU0976567544.SGD","LU1814569148.SGD","LU2237443978.SGD","LU2293690249.USD","LU0203345920.USD","LU1989772923.USD","IE00B4R5TH58.HKD","LU1152091754.HKD","KURE","LU0964806797.USD","BK5011","LU1051770623.HKD","LU2089284900.SGD","LU0949170772.SGD","LU1487256676.USD","LU0920840948.USD","LU1481599808.USD","BK1191","LU1153585028.USD","LU0072913022.USD","LU0211326755.USD","LU0390134368.USD","LU2293690082.USD","IE00BZ08YT58.USD","LU2237443895.HKD","LU2279689827.SGD","LU0969580561.USD","LU2091194634.USD","LU0997586515.USD","LU1481600234.SGD","LU0052756011.USD","LU0140636845.USD","IE00BJJMRZ35.SGD","LU1989772840.SGD","LU0203347892.USD","LU0972486137.USD","01093","300765","LU0315179316.USD","LU0963555726.SGD","LU0122379950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652470300","title":"CSPC Innovation Pharmaceutical Receives China Approval for SYS6043 Clinical Trial; Shares Slide 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652470300","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652470300?lang=en_us&edition=fundamental","pubTime":"2026-07-17 14:33","pubTimestamp":1784269999,"startTime":"0","endTime":"0","summary":"CSPC Innovation Pharmaceutical  subsidiary Jushi Biopharmaceutical received approval from China's National Medical Products Administration for the phase 3 trial of its self-developed SYS6043 drug, according to a Thursday after-hours filing with the Shanghai Stock Exchange.SYS6043 is an antibody-drug conjugate that targets B7-H3 and releases a small molecule toxin to kill tumor cells, the company said in its filing.The trial will evaluate the response in patients with platinum-resistant advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer.Shares in the drug company fell 4% during afternoon trading on Friday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134407705","title":"CSPC Innovation Pharmaceutical's Subsidiary Initiates Phase III Trial for SYS6043","url":"https://stock-news.laohu8.com/highlight/detail?id=1134407705","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134407705?lang=en_us&edition=fundamental","pubTime":"2026-07-16 17:06","pubTimestamp":1784192793,"startTime":"0","endTime":"0","summary":"An announcement has been made by CSPC Innovation Pharmaceutical Co.,Ltd. (ASX: 300765) regarding its majority-owned subsidiary, CSPC Group Jushi Bio-pharmaceutical Co., Ltd. (Jushi Bio). The...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300765","BK0226","BMED","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115861661","title":"Resolutions Passed at CSPC Innovation Pharmaceutical's Third Extraordinary Shareholders' Meeting of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1115861661","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115861661?lang=en_us&edition=fundamental","pubTime":"2026-07-08 22:21","pubTimestamp":1783520505,"startTime":"0","endTime":"0","summary":"Cspc Innovation Pharmaceutical Co.,Ltd. (ASX: 300765) has announced that the resolutions from its third extraordinary shareholders' meeting of the year 2026 have been passed.The meeting, held on July...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155535171","title":"CSPC Innovation Pharmaceutical's Investigational Drug SYS6043 Granted Breakthrough Therapy Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=1155535171","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155535171?lang=en_us&edition=fundamental","pubTime":"2026-07-02 17:05","pubTimestamp":1782983106,"startTime":"0","endTime":"0","summary":"The investigational drug SYS6043 for injection, developed by CSPC Innovation Pharmaceutical Co.,Ltd.'s (300765.SZ) controlling subsidiary CSPC Jushi Biotechnology Co., Ltd., has been included in the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132870129","title":"CSPC Innovation's Subsidiary Forges Strategic Alliance with AstraZeneca on Novel Extrabepatic siRNA Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=1132870129","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132870129?lang=en_us&edition=fundamental","pubTime":"2026-07-02 16:56","pubTimestamp":1782982586,"startTime":"0","endTime":"0","summary":"CSPC Innovation Pharmaceutical Co.,Ltd. (ASX: 300765) has announced a significant strategic partnership.The company's controlling subsidiary, CSPC Group Jushi Biopharmaceutical Co., Ltd., has entered...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0226","LU1267930573.SGD","LU2417539215.USD","LU0029864427.USD","300765","LU0432979614.USD","LU1829250122.USD","LU2456880835.USD","AZNH","LU2089984988.USD","LU0289739699.SGD","IE00B3T34201.USD","159992","LU0128525929.USD","BK1574","06978","LU2237443622.USD","LU0889565916.HKD","LU0109394709.USD","LU0310800379.SGD","LU2237443895.HKD","BK4007","LU0320765992.SGD","LU2462157665.USD","BK4568","BK1161","LU2468319806.SGD","BK4588","LU0708994859.HKD","LU2237443382.USD","LU2237443465.HKD","LU2237443549.SGD","LU2236285917.USD","AZN","LU2237443978.SGD","LU0058720904.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648033025","title":"CSPC Innovation Pharmaceutical Says Unit Signed a Collaboration, Option and License Agreement with Astrazeneca","url":"https://stock-news.laohu8.com/highlight/detail?id=2648033025","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648033025?lang=en_us&edition=fundamental","pubTime":"2026-07-02 16:56","pubTimestamp":1782982578,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nL4N4340PT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648516218","title":"CSPC Innovation Unit Starts Phase III Lung Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2648516218","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648516218?lang=en_us&edition=fundamental","pubTime":"2026-07-01 17:01","pubTimestamp":1782896460,"startTime":"0","endTime":"0","summary":"CSPC Innovation Pharmaceutical  subsidiary CSPC Jushi Biopharmaceutical has launched a Phase III clinical trial for its cancer therapy, SYS6010, according to a Shenzhen Stock Exchange filing on Wednesday.The trial targets patients with resected stage II-IIIB driver gene-negative non-small cell lung cancer who did not achieve a major pathological response after previous treatment.SYS6010 is a novel antibody-drug conjugate approved by China's National Medical Products Administration in June.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0226","300765","III","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170038464","title":"CSPC Innovation's Subsidiary Initiates Phase III Clinical Trial for SYS6010","url":"https://stock-news.laohu8.com/highlight/detail?id=1170038464","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170038464?lang=en_us&edition=fundamental","pubTime":"2026-06-26 18:41","pubTimestamp":1782470467,"startTime":"0","endTime":"0","summary":"CSPC Innovation Pharmaceutical Co.,Ltd. (ASX: 300765) has announced that its controlling subsidiary, Jushi Biopharmaceutical Co., Ltd., recently commenced a Phase III clinical trial for SYS6010.The...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133435698","title":"Prospectus Preview: Caffeine Giant CSPC Innovation Seeks Dual Listing with Second HKEX Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1133435698","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133435698?lang=en_us&edition=fundamental","pubTime":"2026-06-26 10:53","pubTimestamp":1782442419,"startTime":"0","endTime":"0","summary":"A leading caffeine producer on the ChiNext board has expanded into diverse businesses through acquisitions, yet it has reported consecutive annual losses. Can CSPC Innovation Pharmaceutical Co.,Ltd....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300765","IPOS","HEXmain","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645200741","title":"CSPC Innovation Pharmaceutical Updates Hong Kong Listing Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2645200741","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645200741?lang=en_us&edition=fundamental","pubTime":"2026-06-23 12:36","pubTimestamp":1782189380,"startTime":"0","endTime":"0","summary":"CSPC Innovation Pharmaceutical  on June 18 updated its H-share listing application with the Hong Kong Stock Exchange, according to a Monday filing with the Shenzhen bourse.The pharmaceutical company initially filed its application on Dec. 10, 2025.Shares of CSPC Innovation Pharmaceutical rose nearly 1% in recent trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645047017","title":"CSPC says Innovation unit files new Hong Kong listing application after prior lapse","url":"https://stock-news.laohu8.com/highlight/detail?id=2645047017","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645047017?lang=en_us&edition=fundamental","pubTime":"2026-06-22 16:39","pubTimestamp":1782117596,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group updated markets on a proposed H-share listing of subsidiary CSPC Innovation.CSPC Innovation filed a fresh listing application with the Hong Kong Stock Exchange on June 18, 2026, following the lapse of a prior filing.CSPC expects CSPC Innovation to remain an indirect subsidiary if the listing completes.Completion hinges on regulatory clearances, including China’s CSRC, Hong Kong’s Stock Exchange, and the SFC.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 22, 2026, and is solely responsible for the information contained there","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL4TMtlb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0880133367.SGD","LU1226288170.HKD","LU1807302812.USD","BK1191","LU0326950275.SGD","IE00B5MMRT66.SGD","LU0072913022.USD","LU1328277881.USD","BK1521","LU1152091754.HKD","IE00BZ08YS42.EUR","IE0008369823.USD","LU1008478684.HKD","IE00B031HY20.USD","LU1993786604.SGD","IE00BZ08YR35.GBP","HK0000165453.HKD","LU0315179316.USD","LU0501845795.SGD","IE00BZ08YT58.USD","LU0314109678.HKD","LU1226287875.USD","LU0140636845.USD","LU1226287792.SGD","LU2039709279.SGD","IE00B543WZ88.USD","LU1152091168.USD","LU1226287529.USD","01093","LU1226288253.USD","300765","LU1951186391.HKD","LU1960683339.HKD","BK1515","IE0008368742.USD","SG9999004220.SGD","BK0226","LU0067412154.USD","LU1813983027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141720563","title":"Pharmaceutical Firm CSPC Innovation Submits Renewed Listing Application to Hong Kong Exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=1141720563","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141720563?lang=en_us&edition=fundamental","pubTime":"2026-06-20 07:56","pubTimestamp":1781913376,"startTime":"0","endTime":"0","summary":"Information indicates that on June 18, the Hong Kong Stock Exchange disclosed a listing application from Cspc Innovation Pharmaceutical Co.,Ltd. (300765.SZ), targeting the Main Board, with CITIC...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HEXmain","BK0226","IPOS","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112530708","title":"Innovation Pharma Subsidiary Secures Acceptance of New Drug Application for Secukinumab Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1112530708","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112530708?lang=en_us&edition=fundamental","pubTime":"2026-06-18 18:34","pubTimestamp":1781778873,"startTime":"0","endTime":"0","summary":"An announcement has been made by Cspc Innovation Pharmaceutical Co.,Ltd. (300765.SZ) regarding its subsidiary.The company's controlling subsidiary, CSPC JUSHI Biopharmaceutical Co., Ltd., has...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300765","BK0226","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643758228","title":"CSPC Innovation Pharmaceutical Subsidiary Gets Regulatory Nod for Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2643758228","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643758228?lang=en_us&edition=fundamental","pubTime":"2026-06-16 17:43","pubTimestamp":1781603030,"startTime":"0","endTime":"0","summary":"CSPC Innovation Pharmaceutical  unit CSPC Jushi Biopharmaceutical obtained the approval of China's medical products administrator to conduct clinical trials for SYS6041 in combination therapy for ovarian cancer.The potential indications for SYS6041 include solid tumors such as gynecological tumors and lung cancer, according to a Tuesday filing with the Shenzhen bourse.Shares of the pharmaceutical company closed 4% lower Tuesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189715246","title":"CSPC Innovation Pharmaceutical to Alter Stock Ticker to 'CSPC Innovation'","url":"https://stock-news.laohu8.com/highlight/detail?id=1189715246","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189715246?lang=en_us&edition=fundamental","pubTime":"2026-06-16 17:24","pubTimestamp":1781601865,"startTime":"0","endTime":"0","summary":"In a recent corporate announcement, Cspc Innovation Pharmaceutical Co.,Ltd. (ASX: 300765) has declared a change to its stock ticker symbol. The company stated that since 2024, it has leveraged its...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","LU1993786604.SGD","IE00BZ08YT58.USD","161027","IE0008368742.USD","LU1226288170.HKD","LU2039709279.SGD","01093","IE00B543WZ88.USD","LU1152091168.USD","LU1226288253.USD","LU0140636845.USD","HK0000165453.HKD","LU1813983027.USD","BK1515","BK1521","IE00B031HY20.USD","IE00BZ08YS42.EUR","LU0067412154.USD","LU0315179316.USD","LU1951186391.HKD","LU1328277881.USD","LU0501845795.SGD","LU1008478684.HKD","LU0072913022.USD","LU0880133367.SGD","LU1226287792.SGD","LU1226287529.USD","LU1960683339.HKD","300765","BK0226","LU1807302812.USD","LU0314109678.HKD","LU1152091754.HKD","SG9999004220.SGD","LU1226287875.USD","IE0008369823.USD","IE00BZ08YR35.GBP","LU0326950275.SGD","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180875204","title":"CSPC Innovation Pharmaceutical's Subsidiary Receives Clinical Trial Approval for SYS6041 (FRα ADC)","url":"https://stock-news.laohu8.com/highlight/detail?id=1180875204","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180875204?lang=en_us&edition=fundamental","pubTime":"2026-06-15 17:38","pubTimestamp":1781516309,"startTime":"0","endTime":"0","summary":"CSPC Innovation Pharmaceutical Co.,Ltd. (300765.SZ) has announced that its controlling subsidiary, Shijiazhuang Yiling Pharmaceutical Co., Ltd. (referred to as \"Yiling Biotech\"), recently received a...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0226","ADC","300765","BK4080","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108516745","title":"Application Lapses for CSPC Innovation's Hong Kong Share Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=1108516745","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108516745?lang=en_us&edition=fundamental","pubTime":"2026-06-10 11:38","pubTimestamp":1781062707,"startTime":"0","endTime":"0","summary":"It has been learned that the application document submitted by CSPC Innovation Pharmaceutical Co., Ltd. (referred to as CSPC Innovation, 300765.SZ) for its Hong Kong initial public offering, filed on...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","HK0000165453.HKD","BK1191","IE00BZ08YS42.EUR","LU2039709279.SGD","LU1807302812.USD","LU1008478684.HKD","IE0008368742.USD","LU0880133367.SGD","LU0326950275.SGD","IE00B031HY20.USD","LU0067412154.USD","LU0072913022.USD","LU1813983027.USD","IE00BZ08YT58.USD","BK1515","LU1328277881.USD","IE00BZ08YR35.GBP","IE0008369823.USD","LU1226288253.USD","LU1226288170.HKD","LU1226287875.USD","IE00B543WZ88.USD","SG9999004220.SGD","LU0501845795.SGD","LU1951186391.HKD","IE00B5MMRT66.SGD","LU0315179316.USD","300765","LU1226287529.USD","IPOS","BK4588","LU1152091168.USD","01093","LU0314109678.HKD","LU1226287792.SGD","LU1960683339.HKD","BK0226","LU1993786604.SGD","VXUS","LU1152091754.HKD","LU0140636845.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156844864","title":"Subsidiary of CSPC Innovation to Present SYS6043 Phase I Data at 2026 ASCO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1156844864","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156844864?lang=en_us&edition=fundamental","pubTime":"2026-06-02 16:10","pubTimestamp":1780387821,"startTime":"0","endTime":"0","summary":"CSPC Innovation Pharmaceutical Co., Ltd. (ASX equivalent: 300765) has announced that its controlling subsidiary, Shijiazhuang Yiling Pharmaceutical Co., Ltd. (referred to as Yiling Biopharma), will...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1785257950249,"stockEarnings":[{"period":"1week","weight":-0.0615},{"period":"1month","weight":0.5315},{"period":"3month","weight":0.2993},{"period":"6month","weight":-0.1565},{"period":"1year","weight":-0.2574},{"period":"ytd","weight":0.0785}],"compareEarnings":[{"period":"1week","weight":-0.0132},{"period":"1month","weight":-0.0531},{"period":"3month","weight":-0.0716},{"period":"6month","weight":-0.0829},{"period":"1year","weight":0.0599},{"period":"ytd","weight":-0.0392}],"compareStock":{"symbol":"000001.SH","name":"SSE Comp"},"companyName":"石药创新制药股份有限公司","boardCode":"AI0014","boardName":"食品制造业","stockholders":"23758人(较上一季度增加4.55%)","perCapita":"59120股","listingDate":"2019-03-22","address":"河北省石家庄市栾城区张举路62号","registeredCapital":"140459万元","survey":"　　石药创新制药股份有限公司的主营业务是生物制药、功能性原料及保健食品的研发、生产与商业化。公司的主要产品是恩朗苏拜单抗注射液、注射用奥马珠单抗注射液、咖啡因、阿卡波糖、果维康维生素C咀嚼片。公司是国内首批实现mRNA疫苗产业化、ADC与抗体药物管线布局最完整的创新型生物药企业之一，已发展成为集源头创新、临床转化、规模生产与国际商业化于一体的高新技术企业。","listedPrice":24.47},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cspc Innovation Pharmaceutical Co.,Ltd.(300765),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cspc Innovation Pharmaceutical Co.,Ltd.(300765) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cspc Innovation Pharmaceutical Co.,Ltd.,300765,Cspc Innovation Pharmaceutical Co.,Ltd.股票,Cspc Innovation Pharmaceutical Co.,Ltd.股票老虎,Cspc Innovation Pharmaceutical Co.,Ltd.股票老虎国际,Cspc Innovation Pharmaceutical Co.,Ltd.行情,Cspc Innovation Pharmaceutical Co.,Ltd.股票行情,Cspc Innovation Pharmaceutical Co.,Ltd.股价,Cspc Innovation Pharmaceutical Co.,Ltd.股市,Cspc Innovation Pharmaceutical Co.,Ltd.股票价格,Cspc Innovation Pharmaceutical Co.,Ltd.股票交易,Cspc Innovation Pharmaceutical Co.,Ltd.股票购买,Cspc Innovation Pharmaceutical Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cspc Innovation Pharmaceutical Co.,Ltd.(300765),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cspc Innovation Pharmaceutical Co.,Ltd.(300765) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction